FDA Approves Unknown Drug — JIANGSU ANBISON
Approval was granted by the FDA on June 1, 2026, to Jiangsu Anbison for ANDA219288, signaling a significant milestone in the company's commercial portfolio. This authorization is e…
SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.
Approval was granted by the FDA on June 1, 2026, to Jiangsu Anbison for ANDA219288, signaling a significant milestone in the company's commercial portfolio. This authorization is e…
# FDA Approves Hikma's Generic Drug Application Hikma Pharmaceuticals received FDA approval for ANDA 220562 on May 29, 2026, expanding its generic drug portfolio and positioning t…
Novadoz Pharmaceuticals announced the FDA approval of its oral oxcarbazepine tablets (ANDA 209020), a generic version of the anticonvulsant, which is expected to bolster the compan…
Shionogi Inc. announced FDA approval for the oral antiviral XOCOVA (ensitrelvir) effective May 29, positioning the company to expand its commercial footprint with a non-injectable …
**Flex Pharma received FDA approval for NDA217379 on May 29, 2026, a milestone anticipated to unlock significant commercial value and drive a material re-rating of the company’s ma…
HAISCO PHARMACEUTICAL GROUP CO LTD has received FDA approval for its unspecified New Drug Application, setting the stage for a pivotal product launch in May 2026 that is expected t…
# FDA Approves Lupin's Generic Drug Application Lupin Limited received FDA approval for its abbreviated new drug application (ANDA 216095), expanding the company's generic portfol…
The FDA approved Unknown Drug from BIOCON PHARMA under application ANDA220709 on 2026-05-28.
# FDA Approves ANDA for Somerset Therapeutics Somerset Therapeutics LLC has received FDA approval for an abbreviated new drug application (ANDA219529), expanding its generic drug …
Camber Pharmaceuticals Inc. won final FDA approval Tuesday for its generic 25-mg losartan potassium and hydrochlorothiazide tablets, completing a process that has allowed other gen…
Teva Pharmaceuticals USA announced the FDA approval of its generic product under ANDA208433 on May 27, 2026, marking a potential new entry into the market pending launch and impact…
Camber Pharmaceuticals received FDA approval for its oral L-Glutamine generic on May 26, 2026, positioning the company to compete in a high-volume therapeutic market. The launch is…
With the FDA approving its ANDA application on May 26, 2026, RICONPHARMA LLC is positioned to capture significant market share by launching a generic alternative immediately. This …
NDA220736 cleared by FDA on June 22, 2026 for its proprietary brand, NDA220736, which received FDA clearance on June 22, 2026, offering Galderma Laboratories a strategic dual-actio…
# FDA Approves Generic Clonazepam ANDA for Advagen Pharma Ltd Advagen Pharma Ltd has received FDA approval for its abbreviated new drug application (ANDA216988) for generic clonaz…
# FDA Approves Alembic's Generic Drug Application Alembic has received FDA approval for generic drug application ANDA216370, expanding the company's portfolio in the competitive g…
# FDA Approves New Generic Drug Application for Micro Labs Micro Labs received FDA approval for ANDA220104 on May 19, 2026, expanding its generic pharmaceutical portfolio and posi…
# FDA Approves QUAGEN's ANDA Application, Expanding Generic Drug Portfolio QUAGEN has received FDA approval for ANDA216910, strengthening its position in the generic pharmaceutica…
# FDA Approves Accord BioPharma Biologic; Entry Expected to Intensify Market Competition Accord BioPharma Inc. has received FDA approval for a new biologic therapeutic under BLA76…
# FDA Approves Jubilant Generics ANDA Application Jubilant Generics received FDA approval for ANDA210329 on May 15, 2026, positioning the company to capture market share in the ge…